Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.53 |
| ▸ | CTSS | P25774 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | PRKACA | P17612 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | PRKX | P51817 | 1/20 | 0.47 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56596 | 1.00 | CTSK (0.53) | CTSKCTSSMAPTATMPRKACA | |
| SCHEMBL56698 | 1.00 | CTSK (0.53) | CTSKCTSSMAPTATMPRKACA | |
| SCHEMBL21714668 | 0.92 | CTSK (0.51) | CTSKCTSSMAPTATMRIPK1 | |
| SCHEMBL4714695 | 0.92 | CTSK (0.51) | CTSKCTSSMAPTATMRIPK1 | |
| SCHEMBL14168716 | 0.89 | CTSK (0.51) | CTSKCTSSMAPTATMRIPK1 | |
| SCHEMBL4583120 | 0.88 | CTSK (0.53) | CTSKCTSSMAPTATMCTSL | |
| SCHEMBL4961187 | 0.88 | CTSK (0.56) | CTSKCTSSMAPTATMRIPK1 | |
| SCHEMBL28464584 | 0.88 | CTSK (0.53) | CTSKCTSSMAPTATMCTSL | |
| SCHEMBL127326 | 0.88 | RIPK1 (0.60) | CTSKCTSSMAPTATMRIPK1 | |
| SCHEMBL2481921 | 0.88 | RIPK1 (0.60) | CTSKCTSSMAPTATMRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107879963-A | Novel chiral ligands, metallo-chelate, a variety of alpha-non-natural amino acids, the synthetic method of Malawi's promise and its key intermediate | 中国科学院上海药物研究所 | 2018-04-06 | — | — | CN | disclosed |
| CN-106030417-A | Photosensitizing chemically amplified resist material, method for forming pattern using same, semiconductor device, mask for lithography, and template for nanoimprinting | 东京毅力科创株式会社 | 2016-10-12 | — | — | CN | disclosed |
| CN-101875666-B | Optical pure 1,3-alkamine compound as well as preparation method and application thereof in preparing Dapoxetine and analogues thereof | ASTATECH CHENGDU PHARMACEUTICAL CO LTD | 2011-12-28 | — | — | CN | disclosed |
| US-8080570-B2 | α2B and α2C agonists | ALLERGAN, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080570-B2 | α2B and α2C agonists | ALLERGAN, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080570-B2 | α2B and α2C agonists | ALLERGAN, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| CN-101875666-A | Optical pure 1,3-alkamine compound as well as preparation method and application thereof in preparing Dapoxetine and analogues thereof | ASTATECH CHENGDU PHARMACEUTICAL CO LTD | 2010-11-03 | — | — | CN | disclosed |
| CN-101674822-A | compositions and methods for inhibiting cytochrome p450 | SEQUOIA PHARMACEUTICALS INC | 2010-03-17 | — | — | CN | disclosed |
| WO-2009137340-A1 | ALPHA2B AND ALPHA2C AGONISTS | ALLERGAN, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090275627-A1 | ALPHA2B AND ALPHA2C AGONISTS | ALLERGAN, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| EP-1149076-B1 | O-THIOCARBAMOYL-AMINOALKANOL COMPOUNDS, THEIR PHARMACEUTICALLY ACCEPTABLE SALTS AND PROCESS FOR PREPARING THE SAME | SK CORP (KR) | 2003-10-22 | — | — | EP | disclosed |
| US-6620815-B1 | Selective antagonists for human alpha 1A receptors; benign prostatic hyperplasia, impotency, cardiac arrhythmia treatment; anticholesterol agents; intraocular pressure reduction | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-09-16 | — | — | US | disclosed |
| EP-0988295-A4 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002070479-A1 | N-4-PIPERIDINYL COMPOUNDS AS CCR5 MODULATORS | ASTRAZENECA AB (SE) | 2002-09-12 | — | — | WO | disclosed |
| CN-1346346-A | O-thiocarbamoyl-aminoalkanol compounds, pharmaceutically acceptable salts thereof and process for preparing the same | SK CORP (KR) | 2002-04-24 | — | — | CN | disclosed |
| EP-1149076-A1 | O-THIOCARBAMOYL-AMINOALKANOL COMPOUNDS, THEIR PHARMACEUTICALLY ACCEPTABLE SALTS AND PROCESS FOR PREPARING THE SAME | SK Corporation (KR) | 2001-10-31 | — | — | EP | disclosed |
| US-6159990-A | Oxazolidinones as α1A receptor antagonists | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| WO-2000046191-A1 | O-THIOCARBAMOYL-AMINOALKANOL COMPOUNDS, THEIR PHARMACEUTICALLY ACCEPTABLE SALTS AND PROCESS FOR PREPARING THE SAME | SK CORPORATION (KR) | 2000-08-10 | — | — | WO | disclosed |
| EP-0988295-A1 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998057940-A1 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275627-A1 | ALPHA2B AND ALPHA2C AGONISTS | ADRA2B, ADRA2C, ADRB2 | CTSK 2618/4885CTSS 2897/4885MAPT 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.